Limits...
Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia.

Li N, Song Y, Zhou J, Fang B - J Hematol Oncol (2012)

Bottom Line: All patients achieved clinically significant responses to ATO.The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively.So treatment with ATO may be a feasible approach in patients with refractory SAA.

View Article: PubMed Central - HTML - PubMed

Affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital affiliated to Zhengzhou University, Zhengzhou, China.

ABSTRACT
We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.

Show MeSH

Related in: MedlinePlus

Hematopoietic recovery in five patients with refractory aplastic anemia after arsenic trioxide therapy. Bone marrow biopsy specimens were obtained from the five patients. Specimens from pre- and post-treatment (at 8 weeks) were shown. (Hematoxylin and eosin stain; Original magnification: × 100).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3475035&req=5

Figure 1: Hematopoietic recovery in five patients with refractory aplastic anemia after arsenic trioxide therapy. Bone marrow biopsy specimens were obtained from the five patients. Specimens from pre- and post-treatment (at 8 weeks) were shown. (Hematoxylin and eosin stain; Original magnification: × 100).

Mentions: The clinical characteristics of patients and outcomes after ATO treatment are summarized in Tables 1 and2. The overall response rate at 8 weeks was 100% (5/5) after the initiation of treatment, including 20% (1/5) CR and 80% (4/5) PR. The median time to initial response was 43 days (range, 41– 48 days). Four patients with a PR received a second course of ATO and continued to have clinically significant improvements in blood counts. Two of them eventually met response criteria for CR at 17 weeks after the initiation of treatment. So the overall CR rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. Serial bone marrow biopsies showed hematopoietic recovery accompanied by a decrease in adipocyte number in patients after getting a response (Figure1). Actuarial survival was 100% at 1 year and 80% at 2 years. No patient showed evidence of clonal evolution or cytogenetic abnormalities at the last follow-up visit.


Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia.

Li N, Song Y, Zhou J, Fang B - J Hematol Oncol (2012)

Hematopoietic recovery in five patients with refractory aplastic anemia after arsenic trioxide therapy. Bone marrow biopsy specimens were obtained from the five patients. Specimens from pre- and post-treatment (at 8 weeks) were shown. (Hematoxylin and eosin stain; Original magnification: × 100).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3475035&req=5

Figure 1: Hematopoietic recovery in five patients with refractory aplastic anemia after arsenic trioxide therapy. Bone marrow biopsy specimens were obtained from the five patients. Specimens from pre- and post-treatment (at 8 weeks) were shown. (Hematoxylin and eosin stain; Original magnification: × 100).
Mentions: The clinical characteristics of patients and outcomes after ATO treatment are summarized in Tables 1 and2. The overall response rate at 8 weeks was 100% (5/5) after the initiation of treatment, including 20% (1/5) CR and 80% (4/5) PR. The median time to initial response was 43 days (range, 41– 48 days). Four patients with a PR received a second course of ATO and continued to have clinically significant improvements in blood counts. Two of them eventually met response criteria for CR at 17 weeks after the initiation of treatment. So the overall CR rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. Serial bone marrow biopsies showed hematopoietic recovery accompanied by a decrease in adipocyte number in patients after getting a response (Figure1). Actuarial survival was 100% at 1 year and 80% at 2 years. No patient showed evidence of clonal evolution or cytogenetic abnormalities at the last follow-up visit.

Bottom Line: All patients achieved clinically significant responses to ATO.The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively.So treatment with ATO may be a feasible approach in patients with refractory SAA.

View Article: PubMed Central - HTML - PubMed

Affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital affiliated to Zhengzhou University, Zhengzhou, China.

ABSTRACT
We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.

Show MeSH
Related in: MedlinePlus